Shots:
- BI has entered into an agreement with Synaffix (Lonza’s company) to license the latter’s ADC technology, boosting its oncology pipeline via NBE Therapeutics (BI’s subsidiary)
- As per the terms, BI will access Synaffix’s platform for a specified but undisclosed number of targets, with the first target nominated & others to follow within a predefined timeframe in exchange for an upfront, milestones of ~$1.3B & net-sales-based royalties
- Synaffix’s clinically validated platform modifies native glycan anchor sites on antibodies via enzymes to develop ADCs or BsAbs
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim & Synaffix
Related News:- Boehringer Ingelheim Introduces Vetmedin Solution (Pimobendan Oral Solution), for Congestive Heart Failure in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
